Discontinued — last reported Q4 '25
New York Mortgage Trust Free cash flow remained flat by 0.0% to $31.47M in Q4 2025 compared to the prior quarter. Over 2 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 12.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $46.75M | $0.00 | $28.32M | -$64.94M | -$30.40M | -$17.91M | -$4.34M | -$29.54M | -$14.93M | -$19.12M | -$8.56M | -$8.56M | $31.47M | $31.47M | $31.47M | $31.47M |
| QoQ Change | — | -100.0% | — | -329.3% | +53.2% | +41.1% | +75.8% | -580.8% | +49.5% | -28.1% | +55.2% | -0.0% | +467.6% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | -165.0% | — | -115.3% | +54.5% | +50.9% | +35.3% | +42.7% | — | +264.6% | +467.7% | +467.6% | — |